Novel JAK inhibitor pacritinib proves effective for easing symptoms of myelofibrosis

Bookmark and Share
Published: 30 May 2015
Views: 1642
Dr Ruben Mesa - Mayo Clinic Cancer Center, Scottsdale, USA

Dr Mesa presents, at a press conference at ASCO 2015, findings from the PERSIST-1 study of patients with myelofibrosis that suggest that pacritinib is significantly more effective than best available therapy (BAT), which includes a range of off-label treatments.

Read the news article and watch the interview for more.